Oasmia Pharmaceutical, which is developing new formulations of existing chemotherapy drugs for use in humans and dogs, raised $9 million by offering 2.3 million ADSs at $4.06, below the range of $4.70 to $6.70. The offering also included 1.1 million warrants with an exercise price of $4.06 per ADS. The company originally filed to offer ADSs at $5.25-8.25. It currently trades on the Nasdaq Stockholm (symbol OASM) and Frankfurt Stock Exchange (symbol OMAX) and will begin trading on the Nasdaq under the symbol OASM. Rodman & Renshaw and Joseph Gunnar & Co. acted as lead managers on the deal.
